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INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a rare malig-
nant disease with worldwide age-adjusted incidence
rates (per 100,000) of 1.66 amongmen and 0.64 among
women (1). However, it is endemically found in South-
ern China (Guangdong province), Hong Kong and
Singapore. According to the database of the Interna-
tional Agency for ResearchonCancer, thehighest rates
in the world are in Hong Kong with incidence rates of
25 per 100,000 amongmale and 10 per 100,000 among
female (1). Statistics are not available for the Guang-
dong Province in China, where the ratesmay be even
higher. The rates of NPC are intermediate (2 to 6 per
100,000) in other areas of Southeast Asia, such as
Malaysia, Vietnam, Thailand andGuam. In these coun-
tries NPC is also more common in men particularly
of Chinese ancestry.
The World Health Organization (WHO) classifica-
tion distinguishes three histopathological typesofNPC
based on the degree of differentiation. Different preva-
lent histologic types of NPC are found in endemic and
nonendemic regions (2). Keratinizing squamous cell
carcinoma is more common in theWestern countries
(75%) while in endemic areas such as Southern China,
the undifferentiated carcinoma orWHOType III NPC
accounts for more than 97%.
NPC shows a remarkably high cure rate for early-
stage disease, and early detection is critical to improve
the overall prognosis of patients. However, the clinical
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presenting features of NPC are often nonspecific, and
examination of nasopharynx requires expertise and
renders early detection difficult. Diagnosis of NPC
is mainly made by biopsy of the nasopharyngeal mass
(3). At present, the detection of IgA antibodies to EB-
virus specific antigens is the only serological aid to
the diagnosis of NPC (3-4), although the potential
use of serum markers such as the circulating inter-
cellular adhesion molecule 1 (ICAM-1), vascular cell
adhesion molecule 1 (VCAM-1), E-selectin, CYFRA
21-1, tissue polypeptide specific antigen and C-erb
B2 has been proposed (5 -9).
The proteomics approachmay offer a paradigm shift
in studies on the simultaneous expression of serum
proteins in patients with cancer. Detection of selective
or aberrantly expressed serum proteins in cancer pa-
tients may prompt investigations of their potential ap-
plication as novel diagnostic or prognostic biomarkers.
In the present study, wehave subjectedunfractionated
whole sera of ten Malaysian Chinese patients with
NPC and tennormalhealthy controls of the sameethnic
group and range of age to two-dimensional gel elec-
trophoresis (2-DE) and image analysis. The data ob-
tained were then compared to that generated by com-
petitive ELISA as well as immunohistochemical stud-
ies of the patients’ tissues.
MATERIALS AND METHODS
Serum samples.
Serum samples were obtained from tenMalaysian
Chinese patients withNPC (n=7males and n=3 females
with ages ranging from 40-65) prior to treatment at
the University ofMalayaMedical Centre, Kuala Lumpur.
All patients were confirmed histopathologically with
undifferentiated carcinoma orWHOType III NPC for
either stage T1N1M0 or stage T2N1M0. Control
sera were obtained from ten normal healthyMalaysian
Chinese volunteers of comparable gender distribution
and range of age. Serum samples were again collected
from five of the NPC patients (n=3 males and n=2
females) six months after treatment, which involved
radiotherapy and chemotherapy for 3 cycles. Samples
obtained were with consent in accordancewith approval
granted by the Ethical Committee (Institutional Review
Board) of theMedical Centre. All samples were kept
at -20℃ and subjected to similar treatment.
Two-dimensional gel electrophoresis.
2-DE was performed as previously described (10).
Briefly, seven µl (450 µg protein) of unfractionatedwhole
human serum samples were subjected to isoelectric fo-
cusing in rehydrated pre-cast immobilised dry strips
pH 4-7, 11 cm (Amersham Biosciences, Uppsala, Swe-
den). For the second dimension, focused samples in
the strips were subjected to electrophoresis using the
8-18% gradient polyacrylamide gel in the presence of
sodium dodecyl sulphate. All samples were analysed
in triplicate.
Silver staining.
The 2-DE gels were developed by silver staining as
previously described by Heukeshoven and Dernick
(11). For mass spectrometric analysis, gels were stained
according to the method of Shevchenko (12).
MALDI-ToF Pro analysis.
Protein spots were initially identified by comparing
resolved serumprotein profiles with the SWISSExPASy
standard plasma protein reference (13). Confirmation
of the spots ofα1-antitrypsin (AAT),α1-B glycoprotein
(ABG), α2-HS glycoprotein (AHS), complement factor
B (CFB), clusterin (CLU) and the β chain of hapto-
globin (HAP) has been earlier described (10). Identi-
fication of ceruloplasmin (CPL) spots was similarly
performed by using the EttanMALDI-ToF Pro. In gel
trypsin digestion was performed according to the
method of Shevchenko (12).Mass analyses were per-
formed by mixing 1 µl of extracted sample with equal
volume of matrix solution consisting of 10mg/ml alpha-
cyano-4-hydroxy cinnamic acid in 0.5% TFA and 50%
ACN. Only 0.3 µl of the solution was finally spotted
onto the slide loader.
Database search.
The MASCOT programme (www.matrixscience.
com) was used to search protein database.MASCOT
uses peptide mass fingerprints (PMFs) to search da-
tabase for matching peptides from known proteins.
The following parameters were used in the searches :
trypsin digest (onemissed cleavage allowed), species :
Homo sapiens, mass value : monoisotropic, peptide
mass tolerance : ±0.1 Da, peptide charge state : 1+
and NCBInr database. Identification was again con-
firmed using the AmershamBiosciencesEttanMALDI
software.
Image analysis.
Protein spots were analyzed in terms of volume,
performed by using theMolecular Analyst PDQuest
densitometry software (Bio-Rad, Hercules,Calif., USA).
The background was subtracted and analysis was re-
stricted to ten clusters of protein spotswithMr30,000
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distinctively separated by 2-DE, i.e., AAT, ABG, AHS,
CFB, CLU, CPL, HAP and three unidentified proteins
termed PR1, PR2 and PR3. Albumin, serum polypep-
tides having idiotypic and/or allotypic variations (such
as the heavy and light chains of all isotypes of immu-
noglobulins and the α chains of haptoglobin) and the
low Mr protein spots, the majority of which were not
well resolved under the settings of our experiments,
were not assessed. The percentage of volume contri-
bution refers to the volume percentage of a protein
taken against the total spot volume of all proteins in-
cluding the unresolved peptides in each gel.
Competitive ELISA.
Competitive ELISA was performed as previously
described (10). Plates were coated with human serum
at 1 : 1000 dilution in 0.05 M carbonate-bicarbonate
buffer pH 9.6 and blocked with 0.5% gelatin in PBS-
Tween. After washing, plates were incubated with di-
luted sheep anti-humanCPL (Code PC045 ; the Binding
Site Limited, Birmingham, UK), in the absence and
presence of sera of NPC patients and normal controls
at 1 : 1000 dilution in PBS-Tween for 1.5 hr. Blanks
were prepared by addition of PBS-Tween instead. Fol-
lowing extensive washwith PBS-Tween, the plates were
further incubated with 200 µl of diluted horseradish
peroxidase (HRP) conjugated donkey anti-sheep IgG
(Code AP360;the Binding Site Limited, Birmingham,
UK) per well for 1 hr. Enzyme activity was revealed
with 0.5 mg/ml o-phenylenediamine dihydrochloride
and 0.012% (v/v) H2O2 in 1 M sodium citrate buffer
pH 5. Reactions were terminated by addition of 100 µl
H2SO4 and absorbance values were read at 490 nm.
The amount of CPL in the test sera is proportional
to the % inhibition of substrate hydrolysis.
Immunohistochemical studies.
Sections (5 µm thick) from nasopharyngeal lesions
of NPC patients (undifferentiated or WHO type III
carcinoma) were subjected to immunohistochemical
analysis as previously described (10), using sheep anti-
human CPL (1:200 dilution) as the primary antiserum
followed by detection with HRP-conjugated donkey
anti-sheep IgG (1:100 dilution). Both antibodies were
from the same batches of antisera that were used in
ELISA. Negative control was obtained by omission
of the primary antibody. Protein expressionwas scored
as follows : negative if no staining was seen or if im-
munoreactivity was observed in less than 10% of tumor
cells, and positive ifmore than10%of tumorcells showed
staining.
Statistical analysis.
All values are presented as mean± SD (standard
deviation). The Students T-test was used to analyze
the significance of differences between normal sub-
jects and patients. A p value of less than 0.05 was con-
sidered significant.
RESULTS
Separation of unfractionated whole sera of normal
healthy individuals by 2-DE generated typical high
resolution serum profiles comprising only the high
abundance proteins. Under the conditions of our ex-
periments, protein spots that are usually detected by
silver staining include albumin, the heavy and light
chains of IgA, IgG and IgM, α1-antitrypsin, α1-B gly-
coprotein, α2-HS glycoprotein, complement factor B,
clusterin and the β chain of haptoglobin and three other
unidentified protein spot clusters (Fig. 1 a). Studies
confirming the identities of the above known high
abundance acute-phase proteins have been described
recently (10).
When unfractionated serum samples from newly
diagnosed patients with NPC (n=7 males and n=3 fe-
males) were subjected to 2-DE and silver staining
under the same experimental conditions, comparable
results were obtained for both the identified and un-
identified proteins, with exception of a horizontal train
cluster of protein spots which appeared at the 120 kDa
region of the 2-DEgels.When subjected to 2-DE, serum
glycoproteins are often resolved into several different
isoform spots mainly due to the heterogeneity of their
oligosaccharide chains. Fig. 1b demonstrates a typi-
cal representative unfractionated serumprotein profile
of patientswithNPC.The120kDaprotein spots cluster,
which was not expressed in control serum 2-DE pro-
tein profiles, was found present in the serum 2-DE
protein profiles of all NPC patients studied.
When a follow-up 2-DE studywas performed on sera
of five of the patients (3 males and 2 females) who re-
sponded positively to treatment after six months, the
differential expression of the 120 kDa spots clusterwas
apparently normalized in all patients. Fig.1c demon-
strates a typical representative of the unfractionated
serum protein profiles of NPC patients subsequent
to treatment.
Subjecting the 120 kDa gel spots cluster to trypsin
in gel-digestion and mass spectrometry generated a
MALDI-ToF Pro mass spectrum of tryptic peptides
(Fig. 2). MASCOTdatabase search of the peptidemass
fingerprints obtained subsequently identified the up-
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regulated 120 kDa protein spots as that of ceru-
loplasmin (CPL), with 21 matched peaks out of
42 peaks searched, 24 sequencepercent coverage
and aMASCOT score of 86 (MASCOT accession
number gi/1620909).
2-DE is highly reproducible. Our previous report
has indicated that image analysis performed on
triplicate 2-DE gels of serum samples produced
minimal relative standarddeviation in percentage
values of volume contribution of all serumprotein
spots analyzed (10). In the present study, image
analysis performed on the silver-stained 2-DE se-
rum protein profiles of ten NPC patients (prior
to treatment) as compared to ten normal controls
indicated significantly higher expression of CPL
in patients (55-fold ; p=0.0001). However, com-
parable results were obtained for all the other
high abundance serum proteins analyzed (Fig. 3).
Differential expression of CPL, as opposed to con-
trols, was observed in all ten NPC patients that
were studied. Therewas no significant difference
in the relative expression of CPL between
control subjects and NPC patients who received
six months of treatment.
For confirmation of the aberrantly expressed
CPL in sera of theNPCpatients, competitiveELISA
was carried out by using antisera against CPL.
Fig. 4 demonstrates the results of the competitive
ELISA performed in the presence of sera of control
subjects (n=7males andn=3 females),NPCpatients
prior to treatment (n=7 males and n=3 females)
and NPC patients subsequent to treatment (n=3
males and n=2 females). Higher levels of CPL
(0.5-fold ; p=0.0001) were significantly detected
in sera of non-treated NPC patients as compared
to normal controls. Therewas no significant differ-
ence in the levels of CPL that were tested between
treated NPC patients and control subjects.
Fig. 5 demonstrates results of the immunop-
eroxidase studies performed to compare the ex-
pression of CPL in the malignant areas of naso-
pharyngeal lesions of patients with undifferentiated
carcinomaorWHOType IIINPC(n=3malesandn=3
females), which was earlier diagnosed on routine
Hematoxylin&Eosin section staining, as opposed
to their normal epithelial lining (squamous or res-
piratory).TheexpressionofCPLwasweaklypositive
throughout the cytoplasm of cells of the normal
areas of all nasopharyngeal lesionsbutmoderately
to strongly positive in the malignant regions.
Fig.1．Typical2-DE serum protein profiles of normal healthy adult controls
and patients with NPC. Serum samples of normal healthy controls (a) and
patients with NPC prior (b) and subsequent (c) to treatment were subjected
to 2-DE (pI4-7) and silver staining. Besides the detection of albumin (ALB),
immunoglobulin α, γ and µ heavy chains (IHC) and immunoglobulin light
chains (ILC), other high abundance protein spots resolved included α1-
antitrypsin (AAT), α1-B glycoprotein (ABG), α2-HS glycoprotein (AHS),
complement factor B (CFB), clusterin (CLU), the β chain of haptoglobin
(HAP) and three unidentified proteins termed PR1, PR2 and PR3. Com-
parable expression was observed for most of the resolved proteins, with
exception of a120kDaprotein spots cluster (120K), whichwas only detected
in the serum protein profiles of NPC patients prior to treatment. Acid sides
of all 2-DE gels are to the left and relativemolecularmass declines from the
top.
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Fig.２．MALDI-ToF Pro mass spectrum of tryptic peptides derived from the120kDa protein spots cluster.
Identity of the120kDa spots cluster was determined by using the EttanMALDI-ToF Promass spectrometry.
Analysis was performed in reflectron mode. MASCOT database search of the peptide mass fingerprints
obtained subsequently identified the 120 kDa protein spots as that of ceruloplasmin (MASCOT accession
number gi/1620909),with 21 matched peaks(42 peaks searched), a MASCOT score of 86 and 24 sequence
percent coverage.
Fig.3．Mean percentage of volume contribution of 2-DE detectable serum proteins of patients with NPC.
Volumes of protein spots were analyzed by Molecular analyst PDQuest densitometry software (Bio-
Rad, Hercules, Calif., USA). AAT :α1-antitrypsin, ABG :α1-B glycoprotein, AHS :α2-HS glycoprotein, CFB :
complement factor B, CLU : clusterin, CPL : ceruloplasmin, HAP : haptoglobin (β chain), PR1-3 : uniden-
tified proteins. CON, BT and AT refer to normal controls, newly diagnosed patients with NPC prior to treat-
ment and NPC patients subsequent to treatment, respectively. Asterisk denotes value of statistical significant
difference.
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DISCUSSION
Whilst the higher levels of ceruloplasmin (CPL)
in sera of patients with cancers of the kidney, urinary
tract, gastrointestine, cervix, uterus and skinhavebeen
described (14-19), the serum levels of CPL have not
been previously reported for patients with nasopha-
ryngeal carcinoma (NPC). In the present study, the
higher relative expression of CPL of more than fifty-
fold was detected in the sera of allWHO type III NPC
patients, whilst the expression of most of the other
high abundance serum proteins resolved by 2-DE
was comparable to that of the control sera. The sera
of NPC patients generated typical protein profiles that
were visually and analytically discernible for the en-
hanced CPL expression, and they were also different
from our earlier reported 2-DE protein profiles of pa-
tients with breast cancer and fibrocystic disease of the
breast (10).
The enhanced serum expression of CPL in patients
with NPC was also confirmed by competitive ELISA
although the magnitude of change was lower by ap-
proximately a hundred-fold compared to the 2-DE ex-
periments. This is indicative of the gross higher sen-
sitivity of 2-DE as compared to ELISA when used to
differentiate the levels of CPL between patients and
control subjects.
Alteration of the levels of CPL in the sera of NPC
Fig.4．Analyses of serum ceruloplasmin expression by competitive ELISA. Competitive ELISA was performed
using sheep anti-human ceruloplasmin as the primary antiserum, in the presence of sera of control subjects (CON ;
n=7 males and n=3 females) and NPC patients before (BT; n=7 males and n=3 females) and after (AT; n=3 males
and n=2 females) treatment. Analyses were performed in triplicate. The amount of ceruloplasmin in the test
sera is proportional to the % inhibition of substrate hydrolysis.
Fig.5．Immunohistochemical analysis of ceruloplasmin expression
in nasopharyngeal lesions. Nasopharyngeal lesions fromNPC pa-
tients were subjected to immunohistochemical analysis using an-
tiserum to ceruloplasmin. Negative control (NEG) was obtained
by omission of the primary antibody. NOR andMAL refer to the
respective normal and malignant regions of the lesions as earlier
diagnosed on routine Hematoxylin & Eosin section staining.
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patientsmay be attributed to the changes of its synthe-
sis by the liver. CPL is an α2-globulin which contains
approximately 95% of the total serum copper (20). The
synthesis of CPL is controlled by the amountof copper
available to the liver. Like CPL, copper levels were also
elevated in several cancers (21-26), but unlike CPL,
the levels of copper in plasma are not regularly stable
and may fluctuate in the presence of copper lowering
agents like zinc or thiomolybdates (27, 28). Thiomolyb-
dates and zinc lower the copper levels by inhibiting
the absorption of copper into the bloodstream. How-
ever, an initial increase of plasma levels of copper may
occur due to copper release from the liver.
CPL bound copper has been found to act as a mo-
lecular switch for activating proangiogenic factors, e.
g., vascular endothelial growth factor, basic fibroblast
growth factor, interleukin-1 and tumor necrosis factor
alpha (29, 30). Tumors require an extensive network
of capillaries to provide nutrients and oxygen. Thus,
angiogenesis, which is reflected from the level of CPL
(or copper) in plasma, is strongly implicated to support
growth of tumors (31-34). The observed enhanced
expression of CPL in the sera of NPC patients of the
present study provides further support to this widely
accepted notion.
Evidence for the direct association of malignancy
with CPL is found from our immunohistochemical
studies performed on nasopharyngeal lesions of the
NPC patients. By using antiserum toCPL, moderate
to strong positive CPL staining was distinctively de-
tected in the cytoplasm of cells at the region of ma-
lignancy but only weak staining was observed at nor-
mal epithelial lining areas of the lesions. The selective
enhanced expression of CPL at the malignant areas
of the lesions as well as the previous report on the sig-
nificant increase of microvessel density of NPC tissue
as compared with those benign tumors of nasopha-
ryngeal region and nasopharyngeal tissue without tu-
mor (35) are indicative of the direct correlation of an-
giogenesis with malignancy. These results are also
compatible with the earlier reported studies performed
on human cerebral gliomas (36), as well as the folli-
cular and papillary carcinomas of the thyroid (37, 38),
in which various degrees of CPL staining were selec-
tively detected in malignant tissues.
The progression of malignancy inNPCmay also be
reflected by the serum CPL levels. When follow-up
2-DE and ELISA studies were performed on sera of
five of the NPC patients subsequent to treatment for
six months, the differential expression of CPL was
apparently normalized in all patients. Changes in the
expression of CPL in the treated NPC patients may
provide useful information formonitoring progression
of malignancy since all the five NPC patients studied
responded positively to treatment.
Taken together, the data of our 2-DE, ELISA and
immunohistochemical studies performed on the small
cohorts of NPC patients and normal subjects suggest the
potential role of CPL as an additional serumbiomarker
for diagnosis and monitoring ofNPC. In addition, there
is also a possibility that themetastasis of tumor in NPC
may be made stabilized by treatment with copper low-
ering agents due to the correlation of CPLwithmalig-
nancy that is shown in the present study. Such copper
deprivation treatmenthas already claimedconsiderable
success in clinical trials performed on patients with
advanced cancers (28, 39-41).
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